Tirzepatide vs semaglutide: what the trial data shows+

What the tirzepatide vs semaglutide comparison rests on

For years, tirzepatide vs semaglutide comparisons were built from separate trials: tirzepatide's SURMOUNT program against semaglutide's STEP program, run at different times, in different populations, against different placebo groups. That kind of cross-trial comparison is a weak form of evidence. Two direct head-to-head trials have since closed that gap: SURPASS-2 in people with type 2 diabetes, and SURMOUNT-5 in people with obesity but no diabetes diagnosis. Both are covered below with the actual randomized numbers.

Semaglutide activates a single receptor, GLP-1. Tirzepatide activates two, GLP-1 and GIP. That structural difference is the starting point for every mechanistic explanation of why the two drugs produced different results in these trials.

Mechanism: one receptor versus two

Native GLP-1 and GIP are both incretin hormones released from the gut after a meal, and both increase insulin secretion in a glucose-dependent way. Semaglutide is a modified analogue of GLP-1 carrying a fatty acid side chain that binds serum albumin, extending its half-life to roughly one week. Tirzepatide carries a similar side chain but is built to bind both receptors at once, with about 18-fold lower potency at the GLP-1 receptor than native GLP-1 itself and near-native potency at the GIP receptor (Willard et al., 2020, JCI Insight).

That imbalance looks deliberate. Full-strength GLP-1 receptor activation drives much of the nausea associated with this drug class, since GLP-1 receptors sit in brainstem regions tied to the vomiting reflex as well as the hypothalamic regions that reduce appetite. A milder GLP-1 signal paired with added GIP receptor activity is the working explanation for how tirzepatide reaches larger weight-loss effects without a proportional rise in gastrointestinal side effects. GIP receptor activation also improves insulin sensitivity in adipose tissue on its own, though how much of tirzepatide's advantage in the trials below comes from that pathway versus the milder GLP-1 signaling is still being worked out.

SURPASS-2: the type 2 diabetes head-to-head

SURPASS-2 randomized 1,879 adults with type 2 diabetes, 1:1:1:1, to tirzepatide at 5 mg, 10 mg, or 15 mg, or semaglutide at 1 mg, over 40 weeks (Frias et al., 2021, New England Journal of Medicine, n=1,879). At baseline, mean HbA1c was 8.28% and mean body weight was 93.7 kg.

HbA1c fell by 2.01, 2.24, and 2.30 percentage points on the 5 mg, 10 mg, and 15 mg tirzepatide doses, against 1.86 points on semaglutide. All three tirzepatide doses were superior to semaglutide, not merely non-inferior. Body weight fell further too, by an estimated 1.9 kg, 3.6 kg, and 5.5 kg more than semaglutide at the three doses, with P less than 0.001 for every comparison.

Gastrointestinal adverse events came out similar between groups rather than worse on tirzepatide. Nausea occurred in 17% to 22% of tirzepatide participants against 18% on semaglutide, diarrhea in 13% to 16% against 12%, and vomiting in 6% to 10% against 8%. Serious adverse events were reported in 5% to 7% of tirzepatide participants and 3% of semaglutide participants.

SURMOUNT-5: the obesity head-to-head

SURMOUNT-5 tested the same two drugs in a different population: adults with obesity but no diabetes diagnosis, each titrated to their own maximum tolerated dose (10 mg or 15 mg tirzepatide, 1.7 mg or 2.4 mg semaglutide) over 72 weeks (Aronne et al., 2025, New England Journal of Medicine, n=751). Unlike SURPASS-2, dosing was not fixed. Each participant reached the highest dose they personally tolerated, closer to how the drugs are actually prescribed for weight management.

Mean weight loss at week 72 came to 20.2% on tirzepatide against 13.7% on semaglutide, a gap of 6.5 percentage points. Waist circumference dropped 18.4 cm on tirzepatide against 13.0 cm on semaglutide. Both differences reached statistical significance.

Discontinuation from gastrointestinal side effects ran lower on tirzepatide than semaglutide in this trial: 2.7% against 5.6%. That result cuts against a simple story where tirzepatide's larger effect comes at the cost of worse tolerability. In SURMOUNT-5, the opposite held.

What explains the gap

Two head-to-head trials, run in two different populations for two different primary endpoints, both favor tirzepatide with confidence intervals that do not cross zero. Consistency across separate trial populations carries more weight than any single result taken alone.

The GIP receptor mechanism from Willard's group is the leading explanation, but it is not the only variable. SURMOUNT-5 titrated each drug to its own maximum tolerated dose rather than a fixed dose, so the comparison reflects real-world titration ceilings alongside underlying drug potency. Neither trial isolates the GIP contribution by itself; that would need a trial arm with GIP receptor agonism alone, which has not been run for this drug pair.

Tirzepatide's approvals came later than semaglutide's. Mounjaro was approved for type 2 diabetes on May 13, 2022, and Zepbound for chronic weight management on November 8, 2023 (FDA press announcement, November 2023). Ozempic was approved for type 2 diabetes on December 5, 2017, and Wegovy for weight management on June 4, 2021.

Semaglutide's longer approval history means a larger real-world safety dataset exists for it, even with the head-to-head trials above now giving tirzepatide the stronger controlled-trial case on effect size. Our tirzepatide research overview and semaglutide research overview cover each compound's full trial history, and the retatrutide compound page carries specifications for the triple-agonist candidate now compared against tirzepatide in its own head-to-head program.

Handling and storage for research use

Both compounds are lyophilized peptides that ship stable at -20C and require reconstitution with bacteriostatic water before use. Once reconstituted, most stability protocols support storage at 2-8C with use inside 28 to 30 days, though the certificate of analysis for the specific batch should be checked rather than assumed. Our reconstitution guide covers the general steps, and the dosing calculator converts a stated concentration into volume per unit for protocol planning.

Repeated freeze-thaw cycling degrades peptide integrity in both compounds, so aliquoting a reconstituted vial into single-use portions before refrigeration is standard practice rather than drawing from one vial across several weeks. Because both molecules are marketed drugs with published sequences and known masses, a certificate of analysis showing HPLC purity above 99% and a matching mass spectrometry result is the baseline check before either compound enters a protocol.

Sourcing tirzepatide and semaglutide for research in Indonesia

Indonesia's tropical climate is the practical complication for shipping either compound. Ambient temperatures in Jakarta, Surabaya, and Bali routinely exceed 28C, well above the 2-8C range that reconstituted peptide stability data assumes, so a shipment that loses cold-chain integrity between courier handoff and lab freezer carries a real degradation risk rather than a theoretical one.

Importers of research-use peptide compounds in Indonesia operate under oversight from BPOM (Badan Pengawas Obat dan Makanan); researchers should confirm current documentation requirements directly with BPOM rather than relying on a supplier summary. Our storage guide for tropical climates covers humidity and heat exposure in more detail. Zurich Biotech ships with insulated cold packs and tracked couriers to Bali, Jakarta, Surabaya, Yogyakarta, and Bandung, but storage discipline after delivery still determines whether a compound arrives usable weeks later.